non-Hodgkin's Lymphoma
Conditions
Interventions
Trade Name: Cyclophosphamide Injection 1g
Product Name: Cyclophosphamide
Pharmaceutical Form: Intravenous infusion
Sponsors
University Hospitals of Leiceter NHS Trust
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: a) Age =18 years at diagnosis b) Diagnosis of B-cell non-Hodgkin's lymphoma c) Recieving cyclophosphamide as part of standard treatment d) Single or double lumen canteral venous catheter in place e) Written informed consent f) Protocol approval by national and local ethics committee Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Failure to complile with any of the inclusion criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Secondary Objective: To confirm previous preliminary findings that the matabolism of cyclophosphamide differs between those patients with recurrent disease and those who remain disease free after treatment. To identify those patients who will benefit from standard therapy prior to or during early treatment as distinct from those patients who are identified as being at high risk of recurrence. To obtain pharmacokinetic/pharmacogenetic information which could be used in future studies to optimise the treatment of B-cell non-Hodgkin's lymphoma. ;Main Objective: To test the hypothesis that inital response of B-cell non-Hodkin's lymphoma is determined by metabolic and pharmacogenetic factors relating to cyclophosphamide.;Primary end point(s): To identify those patients who will benefit from standard therapy prior to or during early treatment. Those patients who are identified as being at risk of recurrence may be offered treatment modification or alternative therapy in future studies. | — |
Countries
United Kingdom
Outcome results
None listed